Asurayya Worrede
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Asurayya Worrede has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Fatatis
Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, USA
17 shared publications - Allison Toth
Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania
15 shared publications - Anthony DiNatale
Hospital of Parma , Parma , Italy
15 shared publications - Eva Corey
Department of Urology, University of Washington, Seattle, WA 98195, USA
15 shared publications - Felix Y. Feng
Department of Radiation Oncology, University of California San Francisco , San Francisco, CA
15 shared publications - Martin Sjöström
Lund University, Lund, Sweden
15 shared publications
Latest Publications
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
PC3-ML cells transduced with an inducible AR-overexpression construct showed strong mitigation of IL-1β expression (a) and secretion (b), as compared to both wild type, non-transduced cells and transduced cells without doxycycline exposure.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
PC3-ML cells transduced with an inducible AR-overexpression construct showed strong mitigation of IL-1β expression (a) and secretion (b), as compared to both wild type, non-transduced cells and transduced cells without doxycycline exposure.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
PC3-ML cells show no difference in luciferase activity between the wild-type promoter and the AREΔ IL-1β promoter, in which the ARE half-site located at -576 was removed.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
PC3-ML cells show no difference in luciferase activity between the wild-type promoter and the AREΔ IL-1β promoter, in which the ARE half-site located at -576 was removed.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Table TS2 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
Whole genome bisulfite sequencing conducted on a subset of patients with low AR activity and low IL-1β expression revealed 346 CpG sites spanning the IL-1β promoter and gene body on chromosome 2, of which 34 showed significant differences in methylation when comparing patients with similarly low AR activity but having high vs. low expression of IL-1β.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable TS2 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
Whole genome bisulfite sequencing conducted on a subset of patients with low AR activity and low IL-1β expression revealed 346 CpG sites spanning the IL-1β promoter and gene body on chromosome 2, of which 34 showed significant differences in methylation when comparing patients with similarly low AR activity but having high vs. low expression of IL-1β.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Table TS1 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
Primer sequences used for ChIP assay
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable TS1 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
Primer sequences used for ChIP assay
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Table TS1 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
Primer sequences used for ChIP assay
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable TS1 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
Primer sequences used for ChIP assay
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
C4-2B cells exposed to Enzalutamide show a dose-dependent(a) and time- dependent increase in IL-1β expression (b). Removal of enzalutamide after a 15-day treatment resulted in a return of IL-1β expression to control (undetectable) levels (c). Same results were obtained with 15-day hormone-deprivation followed by DHT re-addition (d).
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
C4-2B cells exposed to Enzalutamide show a dose-dependent(a) and time- dependent increase in IL-1β expression (b). Removal of enzalutamide after a 15-day treatment resulted in a return of IL-1β expression to control (undetectable) levels (c). Same results were obtained with 15-day hormone-deprivation followed by DHT re-addition (d).
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Data from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
We report the inverse association between the expression of androgen receptor (AR) and IL1β in a cohort of patients with metastatic castration-resistant prostate cancer. We also discovered that AR represses the IL1β gene by binding an androgen response element half-site located within the promoter, which explains the IL1β expression in AR-negative (ARNEG) cancer cells. Consistently, androgen depletion or AR-pathway inhibitors (ARI) derepressed IL1β in AR-positive cancer cells, both in vitro and in vivo. The AR transcriptional repression is sustained by histone deacetylation at the H3K27 mark in the IL1β promoter. Notably, patients’ data suggest that DNA methylation prevents IL1β expression, even if the AR-signaling axis is inactive. Our previous studies show that secreted IL1β supports metastatic progression in mice by altering the transcriptome of tumor-associated bone stroma. Thus, in patients with prostate cancer harboring ARNEG tumor cells or treated with androgen-deprivation therapy/ARIs, and with the IL1β gene unmethylated, IL1β could condition the metastatic microenvironment to sustain disease progression.Significance:IL1β plays a crucial role in promoting skeletal metastasis. The current standard of care for patients with prostate cancer inhibits the AR-signaling axis in tumor cells and will consequently unleash IL1β production. Thus, hormonal deprivation and AR inhibitors should be combined with targeting IL1β signaling, and screening for DNA methylation on the IL1β locus will identify patients that benefit the most from this approach.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
We report the inverse association between the expression of androgen receptor (AR) and IL1β in a cohort of patients with metastatic castration-resistant prostate cancer. We also discovered that AR represses the IL1β gene by binding an androgen response element half-site located within the promoter, which explains the IL1β expression in AR-negative (ARNEG) cancer cells. Consistently, androgen depletion or AR-pathway inhibitors (ARI) derepressed IL1β in AR-positive cancer cells, both in vitro and in vivo. The AR transcriptional repression is sustained by histone deacetylation at the H3K27 mark in the IL1β promoter. Notably, patients’ data suggest that DNA methylation prevents IL1β expression, even if the AR-signaling axis is inactive. Our previous studies show that secreted IL1β supports metastatic progression in mice by altering the transcriptome of tumor-associated bone stroma. Thus, in patients with prostate cancer harboring ARNEG tumor cells or treated with androgen-deprivation therapy/ARIs, and with the IL1β gene unmethylated, IL1β could condition the metastatic microenvironment to sustain disease progression.Significance:IL1β plays a crucial role in promoting skeletal metastasis. The current standard of care for patients with prostate cancer inhibits the AR-signaling axis in tumor cells and will consequently unleash IL1β production. Thus, hormonal deprivation and AR inhibitors should be combined with targeting IL1β signaling, and screening for DNA methylation on the IL1β locus will identify patients that benefit the most from this approach.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
C4-2B cells exposed to Enzalutamide show a dose-dependent(a) and time- dependent increase in IL-1β expression (b). Removal of enzalutamide after a 15-day treatment resulted in a return of IL-1β expression to control (undetectable) levels (c). Same results were obtained with 15-day hormone-deprivation followed by DHT re-addition (d).
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
C4-2B cells exposed to Enzalutamide show a dose-dependent(a) and time- dependent increase in IL-1β expression (b). Removal of enzalutamide after a 15-day treatment resulted in a return of IL-1β expression to control (undetectable) levels (c). Same results were obtained with 15-day hormone-deprivation followed by DHT re-addition (d).
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
Expression of CMV-AR and TRE-AR constructs in PC3-ML cells, confirmed at the transcript level for both (a) and at the protein level for the TRE-AR following addition of doxycycline to the culture medium (b).
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
Expression of CMV-AR and TRE-AR constructs in PC3-ML cells, confirmed at the transcript level for both (a) and at the protein level for the TRE-AR following addition of doxycycline to the culture medium (b).
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Table TS2 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
Whole genome bisulfite sequencing conducted on a subset of patients with low AR activity and low IL-1β expression revealed 346 CpG sites spanning the IL-1β promoter and gene body on chromosome 2, of which 34 showed significant differences in methylation when comparing patients with similarly low AR activity but having high vs. low expression of IL-1β.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable TS2 from IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
Whole genome bisulfite sequencing conducted on a subset of patients with low AR activity and low IL-1β expression revealed 346 CpG sites spanning the IL-1β promoter and gene body on chromosome 2, of which 34 showed significant differences in methylation when comparing patients with similarly low AR activity but having high vs. low expression of IL-1β.